Supplementary Table 2. Changes in FPG, lipid profiles, body weight, and blood pressure after 12 weeks of treatment with sodium-glucose cotransporter-2 inhibitors as switch therapy

Variable	Baseline	Week 12	LS mean change from baseline (95% CI)	Difference in LS mean change (95% CI)[a]
FPG, mg/dL				
Switch (n=203)	148.4±2.9	134.5±2.3	−19.8 (−24.1 to −15.6)[b]	
DPP4i (n=114)	147.9±3.6	137.0±3.2	−11.2 (−16.8 to −5.6)[b]	-
SU (n=54)	147.4±6.9	126.7±4.3	−21.4 (−29.6 to −13.2)[b]	10.2 (−2.0 to 22.3)
TZD (n=35)	151.3±5.4	138.5±5.3	−10.8 (−21.0 to −0.6)[b]	0.4 (−14.6 to 13.8)
TG, mg/dL				
Switch (n=203)	153.1±6.0	140.1±5.3	−15.1 (−23.1 to −7.1)[b]	
DPP4i (n=114)	153.1±8.5	139.0±6.9	−14.1 (−24.2 to −4.0)[b]	-
SU (n=54)	153.2±11.4	126.2±8.5	−26.9 (−40.9 to −13.0)[b]	12.8 (−8.3 to 33.9)
TZD (n=35)	153.0±12.7	166.3±14.5	13.3 (−4.5 to 31.1)	−27.4 (−52.5 to −2.4)[c]
HDL-C, mg/dL				
Switch (n=203)	45.0±0.8	45.2±0.8	0.1 (−0.8 to 1.1)	
DPP4i (n=114)	45.6±1.1	46.3±1.1	0.9 (−0.4 to 2.2)	-
SU (n=54)	42.6±1.3	43.9±1.3	0.8 (−0.9 to 2.6)	−0.1 (−2.6 to 2.8)
TZD (n=35)	47.0±1.9	44.0±1.7	−2.6 (−4.9 to −0.4)[b]	3.5 (−0.3 to 6.7)
LDL-C, mg/dL				
Switch (n=203)	83.2±1.9	80.0±1.9	−2.9 (−5.8 to 0.1)	
DPP4i (n=114)	83.9±2.7	82.5±2.6	−1.2 (−5.1 to 2.8)	-
SU (n=54)	77.3±3.6	72.4±3.4	−7.0 (−12.5 to −1.6)	5.9 (−2.3 to 14.1)
TZD (n=35)	90.8±3.8	84.6±4.8	−3.5 (−10.4 to 3.4)	2.4 (−7.4 to 12.1)
Body weight, kg				
Switch (n=203)	75.2±1.8	72.8±1.7	−2.4 (−2.8 to −1.9)[b]	
DPP4i (n=114)	71.8±3.2	69.8±3.2	−2.0 (−2.8 to −1.2)[b]	-
SU (n=54)	78.2±2.4	75.5±2.3	−2.4 (−3.4 to −1.5)[b]	0.4 (−1.2 to 2.0)
TZD (n=35)	77.8±3.0	75.0±2.8	−2.7 (−3.7 to −1.6)[b]	0.7 (−0.9 to 2.3)
SBP, mm Hg				
Switch (n=203)	128.8±1.0	124.2±1.0	−5.3 (−7.0 to −3.6)[b]	
DPP4i (n=114)	128.5±1.4	124.5±1.3	−4.2 (−6.4 to −2.0)[b]	-
SU (n=54)	130.5±1.8	125.2±1.9	−4.3 (−7.8 to −0.9)[b]	0.1 (−4.9 to 5.1)
TZD (n=35)	127.2±3.0	121.3±2.1	−6.8 (−11.3 to −2.3)[b]	2.6 (−3.6 to 8.8)
DBP, mm Hg				
Switch (n=203)	76.5±0.7	75.3±0.7	−1.7 (−3.2 to −0.2)	
DPP4i (n=114)	75.7±1.0	75.1±0.9	−0.9 (−2.4 to 0.5)	-
SU (n=54)	77.5±1.4	74.5±1.4	−2.6 (−4.8 to −0.3)[b]	1.6 (−1.6 to 4.9)
TZD (n=35)	78.1±1.9	77.0±1.6	−0.4 (−3.3 to 2.5)	−0.5 (−4.5 to 3.5)

Values are presented as mean±standard error.

FPG, fasting plasma glucose; LS, least square; CI, confidence interval; DPP4i, dipeptidyl peptidase 4 inhibitor; SU, sulfonylurea; TZD, thiazolidinedione; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure.

[a]Difference in the LS mean change, which was calculated as compared to adding MET in add-on group and switching from DPP4i in switch group, [b]P<0.05 from baseline in overall patients and each treatment subgroup, [c]P<0.05 for the between-treatment group difference.